NEW YORK (GenomeWeb News) – GnuBio today said that it has completed a $10 million Series B round of financing with private investors.

The Cambridge, Mass.-based firm didn't disclose the names of the investors but said that the round included investors from its Series A round. GnuBio completed that $8 million Series A round a year ago, and it also declined to disclose the names of the investors at that time.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.

May
09
Sponsored by
SeraCare

This webinar is the last in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.